Regeneron Pharmaceuticals, Inc. REGN

Dupixent remains Sanofi's main growth engine, about 42% of H1 2026 revenue; Regeneron records its share of profits from global Dupixent sales under the Sanofi partnership. Sanofi is broadening beyond Dupixent with Altuviiio, Ayvakit, Sarclisa, Beyfortus and others; Q2 2026 new-drug sales rose 48.3% at constant FX to €1.3 billion, led by Altuviiio, Ayvakit and Sarclisa. Altuviiio hit blockbuster status in 2025; Ayvakit and Sarclisa come via Blueprint Medicines and related assets. Cenrifki and tolebrutinib expand the pipeline, while venglustat for Gaucher is under FDA priority review with EU review ongoing. Sanofi expects launches to generate about €10 billion of annual sales by 2030, versus roughly €25 billion for Dupixent, signaling a shift in revenue mix. Sanofi’s stock trades cheaper than peers with rising earnings estimates; Regeneron’s outlook remains tied to Dupixent’s performance. Diversification beyond Dupixent could meaningfully boost Regeneron’s long-term royalties and growth trajectory.

Regeneron has surged about 40% in the last year, raising questions whether today’s US$801.82 price is justified by earnings power or just momentum. At 18.5x trailing P/E, Regeneron trades below the biotech peer average and the broader market, while Simply Wall St’s Fair Ratio sits higher than the current multiple, signaling potential undervaluation given its economics and risk profile. The analysis hinges on Regeneron’s revenue engines, notably Dupixent, and the stock’s exposure to EYLEA’s performance and biosimilar competition. Bulls point to faster Dupixent expansion and new indications; bears warn about concentration risk and policy/regulatory headwinds. The article emphasizes that fair value, not just multiples, should guide entry decisions and frames the stock as undervalued relative to its tailored benchmark, although growth prospects remain a key driver of any upside. Valuation may imply upside if earnings power holds against biosimilar risk, but growth drivers and concentration risks temper the potential.

Regeneron highlights momentum in EYLEA, with EYLEA HD representing roughly 60% of EYLEA net sales in Q2. It expects low- to mid-teens sequential demand growth for EYLEA in Q3 and Q4 despite biosimilar competition. Dupixent and Libtayo also grew robustly—Dupixent approaching $24 billion annualized sales across nine U.S. indications; Libtayo up more than 30% YoY and gaining traction in U.S. lung cancer. Pipeline catalysts include cemdisiran for generalized myasthenia gravis with an FDA decision in November, PNH data in Q4, and readouts in MASH, Factor XI and melanoma. Regeneron repurchased about $2 billion of stock in H1 and aims to fund the pipeline, external deals, dividends and buybacks. The Sanofi development balance was paid off in Q2, lifting collaboration profits from Q3. Pipeline milestones and accelerating growth in EYLEA HD, Dupixent, and Libtayo could materially improve Regeneron's long-term trajectory.

Regeneron Pharmaceuticals' shares have slipped from all-time highs and sit just under $800, despite improving results. In Q2, revenue rose 17% year over year to $4.3 billion, driven by Dupixent, with Sanofi reporting global net sales of $6 billion for the drug, up 38% YoY. Dupixent remains Regeneron's key growth engine into the early 2030s, and the company plans to defend it with a higher-dose formulation. Eylea and Eylea HD US sales totaled about $1 billion in the quarter, with Eylea HD up 52% while the original version fell 45%, helping offset declines elsewhere. The pipeline includes olatorepatide for obesity (licensed from a Chinese biotech), which has shown strong Phase 3 results in China, along with other efforts in weight management and oncology. The stock looks attractive below $800, supported by dividends and buybacks, though regulatory and clinical risks persist. Strong near- to mid-term growth drivers and a potentially meaningful pipeline could significantly shift trajectory, but depend on regulatory approvals and execution.

Sanofi is overhauling its R&D organization, reassessing its late-stage pipeline under new leadership with a focus on scientific rigor, portfolio risk, and capital allocation rather than preplanned program cuts. Core priorities remain immunology/inflammation, rare diseases, and vaccines, while the company broadens its deal strategy to be phase-agnostic and seeks a roughly 50/50 mix between internal and external innovation. More platform-focused partnerships are expected, and the Regeneron alliance could be expanded with assets like lunsekimig under consideration. Sanofi also aims to rebuild its early-stage research, with Phase I programs anticipated from 2026 to 2028. Updates span lunsekimig, revekimab, duvakitug alfa, frexalimab, riliprubart, and other programs, plus ophthalmology gene therapies and potential regulatory actions. Phase-agnostic dealmaking and expanded Regeneron alliance discussions could meaningfully affect Regeneron's collaboration upside and revenue potential.

StockStory labels Regeneron as a stock to sell and highlights Mettler-Toledo as cautious and ADP as a buy in its take on 1 S&P 500 Stock Worth Your Attention and 2 We Ignore. Regeneron, with a market cap around $79.7B, faces stagnating growth (about 4.6% annual revenue growth over five years), rising capital intensity, and eroding returns on capital, leading to a valuation around $799.18 per share and a forward P/E of 12.9. The report argues Regeneron's profits are aging and growth potential is capped versus smaller peers. By contrast, ADP is praised for consistent double-digit revenue growth and a large free cash flow base, while Mettler-Toledo is viewed cautiously due to softer organic growth and waning returns. The piece frames REGN as a cautionary, large-cap pharma with limited upside in the near term. Negative growth and capital-efficiency concerns could weigh on sentiment and near-term REGN stock performance.

Sanofi projects €25B Dupixent future and broadens M&A pursuits ahead of patent losses. Dupixent patent loss threatens major REGN revenue stream while signaling strategic shifts by partner Sanofi.

Intellia's pipeline advances raise questions on long-term value creation amid rivalry with Regeneron in gene-editing therapies. Rivalry developments may moderately affect Regeneron's competitive positioning in overlapping therapeutic areas.

Regeneron Pharmaceuticals stock receives rare double upgrade from analysts highlighting positive outlook. Double upgrade may lift short-term sentiment but does not alter core operations.

Lawsuits claim misstatements in Regeneron Pharmaceuticals' Fianlimab-Libtayo trials, questioning effects on the company's pipeline narrative and investor outlook. Trial-related lawsuits may dent pipeline credibility and trigger moderate market sentiment shifts without reshaping core operations.

Regeneron reports strong Dupixent growth, flags Cemdisiran as pipeline catalyst, and notes continued EYLEA HD momentum. Core product growth and pipeline catalyst updates directly influence revenue trajectory and investor outlook for Regeneron.

Regeneron targets 2026 catalysts as EYLEA HD and DUPIXENT drive growth. EYLEA HD and DUPIXENT position Regeneron for major growth and trajectory shifts via 2026 catalysts.

Regeneron Pharmaceuticals (REGN) stock evaluation points to bullish potential. Bullish stock assessment may shift investor views on REGN performance.

AbbVie advances past rivals including Regeneron with success for its dual-acting myeloma drug. AbbVie's myeloma drug win highlights Regeneron's trailing position and may pressure its oncology market standing.

Regeneron Pharmaceuticals (REGN) Pasatru approval tests challenge the view that the stock is undervalued. Pasatru regulatory approval directly shapes REGN valuation trajectory and investor positioning.

Regeneron Pharmaceuticals receives FDA approval for Pasatru to treat adult FOP. FDA approval of Pasatru opens new revenue streams for Regeneron in rare disease treatment.

Regeneron secures rare-disease treatment win that may affect upcoming earnings results. Rare-disease success introduces moderate earnings influence without guaranteed trajectory shift.

Regeneron Pharmaceuticals adjusts its strategy after mixed results emerged from melanoma drug trials. Mixed melanoma trial outcomes trigger course adjustment that can moderately influence Regeneron pipeline progress and investor views.

Regeneron Pharmaceuticals secures FDA approval for its drug treating a rare genetic disorder. FDA approval opens new revenue stream and strengthens product pipeline.

FDA clears Regeneron bone disease drug, positioning company to challenge Ipsen in market. FDA clearance for new drug enables direct market challenge to Ipsen with potential revenue and share gains.

FDA approves Pasatru for ultra-rare FOP therapy, driving a 5.4% rise in Regeneron Pharmaceuticals stock. FDA approval of Pasatru adds a new rare-disease therapy and lifts Regeneron market value.

Regeneron expands cancer collaboration, making REGN stock appear undervalued. Expanded cancer collaboration constitutes major strategic move likely to significantly alter company's trajectory and investor sentiment.

Regeneron Pharmaceuticals gains FDA approval for Pasatru™ (garetosmab-grts) as first and only treatment shown to reduce new heterotopic ossification lesions and clinician-assessed flare-ups versus placebo in adults with fibrodysplasia ossificans progressiva. First FDA-approved FOP therapy opens new rare-disease revenue stream and strengthens Regeneron pipeline positioning.

EyePoint's Duravyu underperformed Eylea in Phase III trial for eye treatment. Rival drug setback bolsters Eylea competitive positioning in key market.

Regeneron Pharmaceuticals faces rising earnings estimates, indicating potential upside for its stock. Rising earnings forecasts point to better expected financial results and stock performance.

Biocon launches Yesafili, a biosimilar to Regeneron’s Eylea 2 mg, for commercial sale in the US. Direct biosimilar competition targets Eylea, a core revenue driver for Regeneron.

Regeneron Pharmaceuticals posted Q2 outperformance fueled by pipeline progress and product momentum. Pipeline progress and product momentum indicate major strategic advances likely to shift company trajectory and investor sentiment.

Regeneron Pharmaceuticals, Inc. released Q2 2026 earnings results and forward guidance during its earnings call. Quarterly earnings and guidance directly shape revenue forecasts and investor positioning for REGN.

Regeneron Pharmaceuticals, Inc. (REGN) released its Q2 2026 earnings call transcript covering financial results, business updates and forward outlook. Earnings call transcript discloses quarterly results and guidance that directly shape investor views and stock trajectory.

Regeneron Pharmaceuticals reported record Dupixent sales during its Q2 2026 earnings call. Record Dupixent sales signal major revenue growth and strengthened competitive position.